Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514821-45-00

Acronym

INNWOP2020

Enrollment

Registered

2024-09-08

Start date

2021-05-12

Completion date

Unknown

Last updated

2024-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small-Cell Lung Cancer

Brief summary

Achievment of major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition

Detailed description

Radiologic response according to RECIST/iRECIST, Surgical resection rate, Disease free survival at 1, 2, 3 and 5 years, Overall survival at 1, 2, 3 and 5 years, Feasibility and safety of a neoadjuvant/adjuvant treatment

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGLenvatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Achievment of major pathological response after neoadjuvant immunotherapy in combination with angiogenesis inhibition	—

Secondary

Measure	Time frame
Radiologic response according to RECIST/iRECIST, Surgical resection rate, Disease free survival at 1, 2, 3 and 5 years, Overall survival at 1, 2, 3 and 5 years, Feasibility and safety of a neoadjuvant/adjuvant treatment	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026